Upgrade to SI Premium - Free Trial

Aegis Capital Keeps Amarin (AMRN) at 'Hold'; Cautious on Vascepa for Dyslipidemia Strategy

February 28, 2014 9:22 AM
Aegis Capital reaffirms its Hold rating and $2 price target on Amarin Coop plc (Nasdaq: AMRN) on Friday following Q4 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Analyst EPS View

Next Articles